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DT-diaphorase (NAD(P)H:quinone oxidoreductase (NQO1), Enzyme
Commission No. 1.6.99.2) is a homodimeric flavoenzyme that acts
on a wide range of cytosolic substrates including quinones and
their derivatives (Ernster and Navazio, 1987). DT-diaphorase is
present in many tissues but is most abundant in liver (Jaiswal,
1994) and can also be elevated in colon, liver, and breast tumours
relative to surrounding normal tissue (Schlager and Powis, 1990).
The obligate two-electron reductase activity of DT-diaphorase is
the basis for its postulated role as a defense mechanism against the
carcinogenic effects of quinone xenobiotics, which are reduced to
hydroquinone products by DT-diaphorase, thereby bypassing the
formation of semiquinones and subsequent reactive oxygen inter-
mediates (Ernster and Navazio, 1987). A DT-diaphorase gene
knockout mouse exhibits increased quinone sensitivity, consistent
with its role as a protective mechanism against xenobiotic toxicity
(Radjendirane et al, 1998). A broad variety of structurally unre-
lated compounds have been shown to induce DT-diaphorase
expression (Begleiter et al, 1997).
Many chemotherapeutic agents can be reductively activated by
DT-diaphorase (Workman and Stratford, 1993), but one concern
with the clinical use of these prodrugs is the variability in DT-
diaphorase enzyme activities observed in different tissue types and
tumours. It has also been suggested that the therapeutic index 
of drugs activated by DT-diaphorase can be increased through
transcriptional activators such as 1,2-dithiole-3-thiones which can
selectively induce this enzyme in tumour cells (Begleiter et al,
1997). DT-diaphorase and related nitroreductases are also being
studied as prodrug activating enzymes in virus directed
enzyme–prodrug therapies (Warrington et al, 1998).
Traver et al (1992) identified a C to T base change at position
609 of the DT-diaphorase mRNA which would confer a proline to
serine substitution at amino acid 187 of the DT-diaphorase protein.
This base change has been associated with low or absent DT-
diaphorase activity (Kuehl et al, 1995; Traver et al, 1997), and
transfection of eukaryotic cells with DT-diaphorase expression
vectors containing either a C or T nucleotide at position 609
demonstrated that the proline to serine substitution results in
decreased catalytic activity and protein levels (Misra et al, 1998).
Furthermore, mutant protein purified from an E. coli expression
system exhibited 2% of the enzymatic activity of wild-type DT-
diaphorase (Traver et al, 1997). Allelic distribution of this common
polymorphism is in accordance with the Hardy–Weinberg equilib-
rium with estimates of the frequency of homozygous carriers of the
609T allele ranging from 0.16–0.49 depending on ethnic back-
ground (Kelsey et al, 1997; Traver et al, 1997).
Marshall et al (1991) observed a relationship between DT-
diaphorase activity and mitomycin sensitivity in a group of skin
fibroblast strains donated by members of a cancer-prone family.
However, in one heterozygotic cell strain, 3437T, DT-diaphorase
activity was undetectable (Kuehl et al, 1995), which conflicted with
previous reports showing that the allelic status of the nucleotide
609 polymorphism is a predictor for enzyme activity, with
heterozygotes displaying activities intermediate to homozygous
609C (wild-type) and 609T (mutant) cell strains (Traver et al,
1992). DT-diaphorase mRNA was present in this cell strain in
similar quantities to cells exhibiting high DT-diaphorase activities
although the allelic origin of this mRNA was not determined. 
These results bring into question the reliability of predictions of
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nucleotide 609 polymorphism.
In the present report, a panel of normal human skin fibroblast
cell strains were assessed for the allelic distribution of the
nucleotide 609 polymorphism and the relationship between allelic
status and DT-diaphorase activity. Also, the allelic origin(s) of DT-
diaphorase mRNA expression was determined in 3437T cells, as
well as seven selected strains from the skin fibroblast panel.
MATERIALS AND METHODS
Chemicals and reagents
All reagents used for the DT-diaphorase enzymatic assay were
purchased from Sigma Chemical Co. (St. Louis, MO, USA).
Materials used for genomic and RT-PCR, including AmpliTaq
polymerase, were obtained from Roche Molecular Systems Inc.
(Branchburg, NJ, USA). Hinf I and proteinase K were purchased
from Gibco-BRL (Burlington, ON, Canada) and Nonident P-40,
gelatin, and Tween-20 were obtained from Sigma Chemical Co. 
DT-diaphorase monoclonal antibodies B771 and A180 were kindly
supplied by Dr David Ross (University of Colorado Health Sciences
Center, Denver CO, USA). Mouse anti-β -tubulin was obtained from
Sigma. The protease inhibitor ‘cocktail’ (cat. no. 1697498) was
purchased from Roche Bioscience (Palo Alto, CA, USA).
Cell culture
Skin fibroblast cell strains used in this study were generously
provided by Dr Peter Ray and Ms Nancy Cracknel of the Hospital
for Sick Children, Toronto, Canada. 3437T cells were supplied 
by Dr Malcom Paterson (Cross Cancer Institute, University of
Alberta, Edmonton, Alberta, Canada). All cells were grown in
Alpha Minimal Essential Medium supplemented with 10% fetal
bovine serum (Cansera, Rexdale, ON, Canada) and maintained in
a humidified atmosphere containing 5% CO2 at 37° C.
Genomic PCR-Hinf I RFLP assay
Cells were grown in 175 cm2 tissue culture flasks (Nalge Nunc
International, Denmark), harvested by scraping and centrifuged at
250 g. The pellet was resuspended in 1 ml lysis buffer (50 mM
KCl, 10 mM Tris-HCl (pH 8.3), 2.5 mM MgCl2, 0.5 µ g proteinase
K, 0.1 mg ml–1 gelatin, 0.45% Nonident P-40, and 0.45% Tween-
20) and heated at 55° C for 1 h followed by 95° C for 10 min. To
assess the status of the nucleotide 609 polymorphism, primers
were used to amplify the entire coding region of exon 6 producing
a 405 bp product containing nucleotide 609 as well as a native
Hinf I site, as described previously (Goldberg et al, 1998).
DT-diaphorase assay
DT-diaphorase enzyme activity was measured using the substrate
2,6-dichlorophenolindophenol (DCPIP) as previously described
(Misra et al, 1998).
mRNA profile assessment of nucleotide 609
polymorphism
Total RNA was isolated from selected fibroblast strains using the
RNeasy Mini Extraction Kit (Qiagen Inc., Santa Clarita, CA,
USA). 5 µ g of total RNA was reverse transcribed using the
SuperScript II Preamplification Kit (Gibco) and a DT-diaphorase
gene-specific primer 5′ TCC CAA CTG ACA ACC AGA TC 3′
(nt 841–860 of DT-diaphorase cDNA) according to the protocol of
the manufacturer. 10% of the RT reaction was PCR amplified in a
mixture (50 µ l total volume) containing reaction buffer (50 mM
KCl, 10 mM Tris-HCl (pH 8.3), and 0.001% (w/v) gelatin), 1.25
mM MgCl2, 0.2 mM dNTP mix and 5 U AmpliTaq Polymerase
with 100 ng each of DT-diaphorase gene-specific primer: forward
5′ GCC ATT CTG AAA GGC TGG TT 3′ (nt 381–400 DT-
diaphorase cDNA); reverse 5′ CCA TCA CTT GGG CAA GTC
CA 3′ (nt 821–840 DT-diaphorase cDNA).
The 460 bp fragment was amplified using a ‘Touchdown’ PCR
protocol (Don et al, 1991) consisting of a 3 min denaturation at
94° C, two cycles of 1 min denaturation at 94° C, 1 min annealing at
60° C, and a 2 min polymerization at 72° C, 12 cycles in which the
annealing temperature was decreased by 1° C until a touchdown
temperature of 48° C was reached, an additional 17 cycles with the
48° C annealing temperature, and a final extension for 
10 min at 72° C. The PCR product was digested with Hinf I, frac-
tionated on a 1.2% agarose gel, and visualized by ethidium
bromide (10 µ g ml–1) staining. The wild-type (609C) DT-
diaphorase allele generates a 377 bp Hinf I fragment, whereas the
variant allele (609T) produces two Hinf I fragments of 226 and
151 bp. A constitutive 83 bp Hinf I fragment is produced in addi-
tion to the ones derived from the wild-type and variant alleles but
not observed under the these gel electrophoresis conditions and
served as a positive cutting control.
Western blot analysis
DT-diaphorase protein expression was verified in selected cell
strains. Fibroblast strains were grown to a density of 5 × 106 cells
in 175 cm2 tissue culture flasks, harvested by scraping, pelleted at
250 g for 5 min. Pellets were resuspended in PBS containing
protease inhibitor ‘cocktail’. Cell extracts were prepared, protein
concentrations were determined and Western blot analysis carried
out was as previously described (Misra et al, 1998).
RESULTS
609T nucleotide substitution correlates with reduced
DT-diaphorase activity in a panel of 45 normal human
fibroblast cell strains
The C to T base change in nucleotide 609 of DT-diaphorase
cDNA, predicted to confer a proline to serine substitution in amino
acid 187 of DT-diaphorase protein, has been shown to impair
catalytic activity and may result in protein instability (Traver et al,
1997; Misra et al, 1998). The 609T nucleotide substitution
produces a novel Hinf I restriction site (RFLP) in the codon for
amino acid 187, which can be used to screen genomic material for
this variant allele (Goldberg et al, 1998). RFLP analysis of 45
human skin fibroblast cell strains, whose characteristics are shown
in Table 1, resulted in the following allelic distribution of the
nucleotide 609 polymorphism: 60% wild-type for both alleles
(C/C fibroblasts); 35.5% heterozygous (C/T fibroblasts); and 4.5%
homozygous for the variant allele (T/T fibroblasts). Thirty-one of
the strains were assessed independently 2–3 times with complete
consistency of results.
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diaphorase activity is shown in Figure 1. Each assay for enzymatic
activity was run using three different concentrations of cell lysate
and the resulting data was averaged to give a value which is
plotted in the Figure. Repeat independent measurements with five
of the cell strains which were C/C and three of which were C/T in
genotype gave means with standard errors which were approxi-
mately plus or minus 20% of the mean (n = 3–4). C/C and C/T
fibroblasts displayed a wide range of DT-diaphorase activities,
where the group homozygous for the wild-type (609C) DT-
diaphorase allele had significantly greater enzymatic activities
than heterozygous (609C/609T) cell strains (Mann–Whitney Rank
Order Analysis, α < 0.01 for a two-sided test) with the former
showing 2-fold greater mean DT-diaphorase activities (754 ± SD
404 nmol min–1 mg protein–1) than the latter (324 ± SD 118 nmol
min–1 mg protein–1). In two fibroblast strains that were homozy-
gous for the variant allele, DT-diaphorase activity was extremely
low to undetectable. These results are consistent with the notion
that the 609T substitution impairs the catalytic activity and/or
stability of DT-diaphorase, and that a correlation exists between
609T allelic status and DT-diaphorase activity in the individual
cell strains studied.
DT-diaphorase mRNA profile of 3437T fibroblasts
The 3437T cell strain is unusual in that it is heterozygous for 
the DT-diaphorase nucleotide 609 polymorphism but contains
undetectable enzymatic activity (Marshall et al, 1991; Kuehl et al,
1995). These previous studies have shown that total DT-
diaphorase mRNA levels in 3437T cells are similar to other cell
strains displaying detectable enzymatic activity. Because cells that
are homozygous for the variant allele display very low to unde-
tectable DT-diaphorase activity, one possible explanation for the
low DT-diaphorase activity in 3437T cells is that they express the
variant 609T allele exclusively. To examine this question, the rela-
tive levels of expression of the two alleles in 3437T cells was
compared to seven selected fibroblast strains from Table 1 that are
homozygous for the wild-type allele (three strains), heterozygous
(two strains) or homozygous for the variant allele (two strains).
Total RNA isolated from each cell strain was PCR-amplified. As
shown in Figure 2, the DT-diaphorase mRNA expression profile in
the group of fibroblasts from Table 1 was in agreement with the
genomic status of the nucleotide 609 polymorphism (with
heterozygotes expressing DT-diaphorase mRNA from both
alleles). However, 3437T cells displayed an RFLP pattern consis-
tent with fibroblast strains that are homozygous for the variant
(609T) allele, indicating that DT-diaphorase mRNA expressed in
3437T cells arises exclusively from the variant (609T) allele.
Because expression of the 609T variant allele has been associ-
ated with reduced DT-diaphorase protein levels (perhaps due to a
decrease in protein stability), we also examined DT-diaphorase
protein levels in 3437T cells relative to this same panel of seven
fibroblast cell strains from Table 1. As shown in Figure 3, DT-
diaphorase protein levels in 3437T cells were reduced relative to
homozygous wild-type and heterozygous cell strains, to levels that
were similar to that in the two fibroblast strains homozygous for
the variant allele. This is consistent with the RT-PCR analysis
pointing to exclusive expression of the variant 609T allele in
3437T cells. The enzymatic activity in all three of these cell strains
was less than 20 nmol min–1 mg protein–1.
DISCUSSION
The probability that cells will fail to activate bioreductive prodrugs
or inactivate xenobiotics that are substrates for DT-diaphorase, due
to expression of the 609T variant isoform, has been estimated by
measuring the prevalence of the 609T allele in various popula-
tions. The frequency of the polymorphism varies between ethnic
groups; with 2.5–25% of individuals homozygous for the variant
609T allele (Kelsey et al, 1997). The variant allele has also been
examined in different tumour cell types, with reduced frequencies
compared to disease-free reference groups observed in lung (Chen
et al, 1999), and increased frequencies in certain infant leukaemias
(Wiemels et al, 1999). However, studies showing no significant
differences in variant allele frequencies in tumours have also been
reported (Traver et al, 1997). A benzene-exposed population
stratified into haematological malignancy and case control groups
displayed a higher occurrence of the variant allele in the former
group (Rothman et al, 1996), consistent with the possibility that
1000 V Misra et al
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Table 1 Characteristics of skin fibroblast strains used for allelic status and
DT-diaphorase activity determination
Number of strains 45†
Percent male donors 55
Percent female donors 45
Average donor age 3 years (1 day–22 years)
Average strain passage number 9 (6–14)
† Allelic status of nt 609 polymorphism: 27 (60%) C/C, 16 (35.5%) C/T, 
2 (4.5%) T/T
751± 404
324± 118
C/C C/T T/T
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Figure 1 Relationship between allelic status of nucleotide 609
polymorphism and DT-diaphorase activity. Each point represents an
individual assessment of Hinf I polymorphism status (allelic status of
nucleotide 609 polymorphism) and DT-diaphorase activity for a single cell
strain in a group of 45 normal human skin fibroblast strains. There was some
overlap of data points. Mean ± SD DT-diaphorase activity of the group
homozygous for the wild-type allele and the heterozygote group are indicatedexpression of the variant allele can impair the defense mechanism
of the cell against carcinogenesis mediated by certain xenobiotics.
Estimating the magnitude of the response of individuals or cell
populations to xenobiotics or prodrugs that are DT-diaphorase
substrates on the basis of the allelic status of the nucleotide 609
polymorphism will depend on the extent to which allelic status
reflects enzyme activity. The variant 609T allele has been impli-
cated as a marker for some diseases associated with insufficient
detoxification of xenobiotics by DT-diaphorase, and occurs at a
higher frequency in some tumours. However, the absence of
significant levels (Marshall et al, 1991; Kuehl et al, 1995) of DT-
diaphorase activity in at least one human cell strain heterozygous
for the variant allele, 3437T, brought into question the relationship
between genotype and phenotype. In this study we have re-exam-
ined the prevalence of the DT-diaphorase nucleotide 609T substi-
tution in the normal population using 45 normal fibroblast cell
strains derived from skin biopsies (Table 1), and have used this
information to investigate the correlation between genotypic status
and DT-diaphorase activity.
The variant 609T allele occurred with a frequency of 0.21 in our
panel of 45 normal human skin fibroblast cell strains, with a distri-
bution that is in accordance with Hardy–Weinberg equilibrium and
is consistent with previous reports (Kelsey et al, 1997). However,
the aforementioned variation in frequency based on ethnicity may
be relevant as a risk factor for disease associated with environ-
mental and dietary exposures, as hypothesized for other drug
metabolizing enzymes that display genetic polymorphisms
(Nebert et al, 1999). The ethnicity of all the donors in the present
skin fibroblast panel was not revealed. Limited information indi-
cated that they represented a mixture of ethnic backgrounds.
Fibroblasts homozygous for the wild-type (609C) allele
displayed on average 2-fold greater DT-diaphorase activities as
compared to heterozygous fibroblast strains in this panel. This
observation is consistent with a gene–dosage effect arising from
expression of the single wild-type 609C allele in heterozygous
strains. The two homozygous 609T fibroblast strains contained
very low to undetectable enzyme activities in agreement with all
reports of other groups. However, considerable overlap in enzyme
activity was observed between the individual homozygous wild-
type 609C and heterozygous fibroblast cell strains. A likely expla-
nation for the broad range of enzyme activities within these two
groups is a variation in the levels of DT-diaphorase mRNA
expressed in each cell strain. Traver et al (1992) observed a strong
correlation between DT-diaphorase mRNA levels and enzyme
activity in a colon cancer cell panel using a semi-quantitative RT-
PCR technique. Siegel et al (1999) also showed that quantification
of DT-diaphorase protein levels in human saliva was directly
correlated with the DT-diaphorase nucleotide 609 genotype with
C/C individuals showing twice the protein level as C/T individuals
and T/T individuals having undetectable levels. A similar overlap
between C/C individuals and C/T individuals was seen in this
work.
The 3437T cell strain in unique among cell strains in the present
work and in previous studies, in that it is genetically heterozygous
but displays undetectable DT-diaphorase activity. Western blot
analysis indicates that these cells express DT-diaphorase at lower
Genotype vs activity of a DT-diaphorase mutation 1001
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Figure 2 DT-diaphorase allelic mRNA expression profiles. Seven skin
fibroblast strains from Table 1 and 3437T cells were examined for wild-type
and variant DT-diaphorase mRNA expression as described in Materials and
Methods. The 377 bp band corresponds to wild-type allele expression while
the 226 and 151 bp bands correspond to variant allele expression. Lanes
1–3, fibroblasts homozygous for the wild-type DT-diaphorase allele; Lanes 4
and 6, heterozygous fibroblasts; Lanes 7 and 8, fibroblasts homozygous for
the variant allele; Lane 5, 3437T cells. L = 123 bp DNA size marker ladder
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Figure 3 Western blot analysis of DT-diaphorase protein levels in normal
human skin fibroblast strains and 3437T cells. Immunoblot analysis was
performed on total protein extracts using a mixture of DT-diaphorase
monoclonal antibodies B771 and A180 as described in Misra et al (1998).
Blots were also probed for β -tubulin expression as a protein-loading control.
Lanes 1–3, normal human fibroblasts homozygous for the wild-type (609C)
DT-diaphorase allele; Lanes 4 and 6, heterozygous fibroblasts; Lanes 7 and
8, fibroblasts homozygous for the variant allele (609T); Lane 5, 3437T cells.
Lanes 5, 7, and 8 were intentionally loaded with 2-fold the protein as the
other lanes. Also shown are DTD: β -tubulin expression for these strains as
determined by densitometry. Values represent mean ± SD of five
densitometric readings for each lane standardized to 3437T cells1002 V Misra et al
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levels than cells homozygous for the wild-type allele, perhaps due
to instability of the variant isoform. RT-PCR analysis confirmed
that the variant allele is expressed exclusively in 3437T cells.
Therefore, although 3437T cells represent an extreme case, they
illustrate a potential problem in the use of allelic status of the
nucleotide 609 polymorphism to predict DT-diaphorase activity 
in heterozygotes. The overlap in enzymatic activities observed
between homozygous wild-type 609C and heterozygous fibro-
blasts also illustrates the difficulty in distinguishing C/C from C/T
cells on the basis of enzyme activity, although such cell strains are
clearly distinguishable from T/T cell strains.
The absence of measurable DT-diaphorase mRNA expression
from the C allele in 3437T cells may be due to methylation leading
to maternal or paternal gene silencing or to defects in the upstream
promoter region effecting basal transcription. Similarly, the varia-
tion in DT-diaphorase activities observed within groups of C/C
and C/T cells may reflect individual differences in transcriptional
responses, given the complexity of pathways involving the xeno-
biotic response element and the aromatic response element
(Favreau and Pickett, 1991) and their corresponding cis- and
trans-acting factors.
In conclusion, accurate prediction of cellular responses to
prodrugs and xenobiotics that depend on DT-diaphorase activity
can be based to a first approximation on genotype status, which
can distinguish between significant levels of enzyme activity in
homozygous wild-type and heterozygous cells and very low to
undetectable levels of enzyme activity in homozygous variant
cells. Although heterozygotes have on average half the activity of
wild-type cells, the ranges are overlapping. The existence of a
heterozygous cell strain with no detectable DT-diaphorase activity,
due to allele-specific expression, does not appear to be a common
occurrence and thus will not play a large role in predictions based
on genotyping.
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